The data were published in the peer-reviewed Journal of Clinical Pathology which highlighted Biocept’s flagship Target Selector qPCR Assay using "Switch Blocker" technology that collects and analyzes molecular markers linked to tumors in circulating tumor cells, as well as plasma.
“Results from this study showed a very high concordance rate between our liquid biopsy testing and tissue biopsy, providing further clinical validation of our Target Selector technology," said Dr Veena Singh, senior vice president and senior medical director, in a statement.
"Our clinical testing demonstrates best-in-class detection of alterations down to a single mutant copy, not only in an analytical setting but in a clinical setting as well. Further, the ability to inform clinical decision making in a significantly more cost-effective manner potentially affords the healthcare system a highly sensitive and cost-effective option," Singh added.
The San Diego-based company said the study examined 127 clinical assays for mutations commonly associated with cancer found in the EGFR, BRAF and KRAS genes. Each Target Selector assay in the study demonstrated extremely high accuracy, sensitivity and specificity when compared to results obtained from tissue samples, showing a 93%-96% concordance to blinded tissue samples across all assays.
"The continued validation of our technology demonstrates its ability to non-invasively identify biomarkers specific to cancer, and to aid physicians in selecting optimal therapeutic treatments for their patients," said CEO Michael Nall.
"We are pleased to report that our biomarker testing has been performed in more than 25,000 patients to date, and results from this study further illustrate the enhanced performance of our Target Selector technology."
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham